Veradermics (MANE) SEC filings document the formal record behind the company’s late-stage dermatology drug development business. As a clinical-stage biopharmaceutical company focused on VDPHL01 for pattern hair loss, its filings are especially useful for reviewing clinical disclosures, financing activity, equity structure, compensation plans, and quarterly operating updates.
Quarterly reports on Form 10-Q provide detail on items such as marketable securities, stock-based compensation, common and preferred stock matters, pre-funded warrants, and other financial statement notes. Annual reports on Form 10-K, when filed, provide a fuller business and risk-factor record. For Veradermics, these periodic reports are important because the company’s public materials focus on clinical development rather than sales of an approved commercial product.
Form 8-K filings have been used by Veradermics to report material events, including financial results, Regulation FD disclosures, clinical trial data releases, public offering activity, and private placement activity. S-1 registration statements provide information about registered securities, underwriting terms, IPO-related matters, preferred stock conversion, related-party disclosures, and beneficial ownership tables. Form 4 filings, when filed, show insider transactions involving officers, directors, or other reporting persons.
For MANE filing research, key documents include 10-Q quarterly reports, future 10-K annual reports, S-1 registration statements, 8-K material-event reports, and any Form 4 insider transaction reports. Together, these filings show how Veradermics funds development, structures equity, and reports progress for its investigational dermatology program.
Veradermics, Inc. (MANE) received an updated Schedule 13D/A from investment entities associated with Montanova Capital, LLC and Aaron Cowen, detailing their current beneficial ownership and recent trades. Montanova Capital and Mr. Cowen report beneficial ownership of 3,718,970 shares of common stock, representing 8.8% of the outstanding shares, through Averill Master Fund, Ltd. and Averill Madison Master Fund, Ltd.
On August 19, 2026, Averill Master Fund sold 690,601 shares and Averill Madison Master Fund sold 59,399 shares in open-market transactions at $107.25 per share. On August 20, 2026, Averill Master Fund exercised Pre-Funded Warrants for 149,000 shares and Averill Madison Master Fund exercised Pre-Funded Warrants for 151,000 shares at $0.00001 per share, funded from the Funds’ working capital.
Veradermics, Inc (MANE) had multiple entities associated with the reporting group, including Montanova Capital, LLC and Averill funds, report transactions in its securities. On 2026-08-20 they exercised 300,000 Pre-Funded Warrants into 300,000 shares of common stock, all reported as indirect ownership. On 2026-08-19 they reported indirect open-market or private sales of an aggregate 750,000 shares of common stock at a reported price of $107.25 per share. Resulting ownership balances are not provided in the data shown.
Veradermics, Inc (MANE) had an initial statement of beneficial ownership filed for David Hollander, who serves as Chief R&D Officer. The filing reports no transactions and no beneficial ownership positions in Veradermics securities as of the reporting date.
Veradermics, Inc. (MANE) is the issuer for a proposed sale by its affiliate Averill Master Fund, Ltd. of 690,601 common shares, with an aggregate market value of $74,066,957.25. The approximate sale date is August 19, 2026, and BofA Securities, Inc. is listed as broker. The fund acquired the shares on February 5, 2026, through conversion of the issuer’s Series B Preferred Stock, which it acquired on November 25, 2024.
Veradermics, Inc (MANE) reported that its Chief Technical Officer, Timothy August Durso, exercised stock options for 3,452 shares of Common Stock at an exercise price of $12.19 per share and on the same date sold an aggregate of 43,500 Common shares in multiple open-market transactions at weighted average prices ranging from about $106.71 to $111.28 per share. The option was fully vested and exercisable, and the transactions were made pursuant to a Rule 10b5-1 trading plan.
Veradermics, Inc (MANE) reported insider activity by Chief Executive Officer Reid Alexander Waldman. On 2026-08-17 he exercised 3,452 stock options to acquire an equal number of common shares at an exercise price of $12.19 per share from a fully vested option. On the same date, he reported open-market sales totaling 67,500 common shares in multiple tranches at reported weighted-average prices between $106.07 and $111.28 per share, executed pursuant to a Rule 10b5-1 trading plan.
MANE has a planned resale of restricted securities under Form 144. The filing lists up to 87,000 shares of common stock to be sold through J.P. Morgan Securities LLC on the NYSE, with a proposed sale date of August 17, 2026.
The 87,000 shares are composed of 3,452 shares associated with stock options originally dated March 24, 2020, and 83,548 founder shares from the same date. These are sales by an existing holder, not a new issuance by the company.
MANE has filed a notice of proposed sale of 135,000 shares of common stock under Form 144. The filing lists an aggregate market value of $15,022,800 for these shares and shows 41,780,136 shares outstanding as of 08/17/2026 on the NYSE.
The 135,000 shares consist of 3,452 shares acquired through a stock option and 131,548 founder shares, both originally acquired from the issuer. No sales of these securities are reported during the past three months.
Veradermics, Inc. shareholder SR One–affiliated funds amended their beneficial ownership report after selling shares in a private transaction. On August 12, 2026, SR One Capital Fund II Aggregator and AMZL sold an aggregate of 321,749 Veradermics common shares at $104.30 per share, for total consideration of approximately $33,558,420. After the sale, SR One Capital Fund II Aggregator holds 1,403,959 shares and AMZL holds 676,160 shares, for a combined total of 2,080,119 shares, representing 4.9% of Veradermics’ common stock outstanding based on 41,780,136 shares reported as of August 6, 2026. The reporting persons state they have no current plans regarding control-related actions involving Veradermics but note the funds may dispose of additional shares depending on market conditions. As of August 12, 2026, each reporting person has ceased to beneficially own 5% or more of the issuer’s common stock.